转染技术市场:现状分析及预测(2022年～2028年)

转染技术的市场规模，在预测期间内预计以约8％的年复合成长率扩大。转染改变宿主细胞遗传内容的能力在研究正常细胞过程、疾病的分子机制和基因治疗的功效方面具有广泛的应用。转染作为遗传基因或遗传基因物产的功能和控制的研究，基因转殖生物的生产，及基因治疗的方法，成为强力的分析工具。

本报告提供全球转染技术市场相关调查，市场概要，以及各类型，各用途，各技术，各终端用户，各地区的趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 市场简介

第2章 调查方法或假设，市场定义

第3章 市场摘要

第4章 摘要整理

第5章 COVID-19对转染技术市场的影响

第6章 转染科技市场收益(10亿美元)，2020年～2028年

第7章 各产品类型的市场洞察

• 试剂
• 设备
• 其他

第8章 各用途的市场洞察

• 治疗药给药
• 生物医学研究
• 蛋白质产生
• 其他

第9章 各技术的市场洞察

• 物理的转染
• 生物化学为基础的转染
• 病毒载体为基础的转染

第10章 各终端用户的市场洞察

• 研究中心、学术机构
• 医院、诊疗所
• 製药公司、生物科技企业
• 其他

第11章 各地区的市场洞察

• 北美
• 欧洲
• 亚太地区
• 其他地区

第12章 转染技术市场动态

• 推动市场要素
• 市场课题
• 影响分析

第13章 转染技术的市场机会

第14章 转染技术的市场趋势

第15章 需求面和供给方面的分析

第16章 价值链分析

第17章 竞争模式

第18章 公司概要

• Lonza Group Ltd.
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories Inc.
• Roche
• QIAGEN
• Mirus Bio LLC
• SignaGen Laboratories
• Genlantis Inc.
• OZ Biosciences
• Promega Corporation

第19章 免责声明

The transfection technologies market is expected to witness a CAGR of around 8% during the forecast period. Transfection is a modern and powerful method used to insert foreign nucleic acids into eukaryotic cells. The ability to modify host cells' genetic content enables the broad application of this process in studying normal cellular processes, disease molecular mechanisms, and gene therapeutic effects. Biosimilar drug development is accelerated as several drug patents are anticipated to lapse in the coming years. A combination of cytological, genomic, and proteomic analysis is crucial to their development. As a result, the use of transfection equipment and reagents in proteomic and genomic research has grown. Furthermore, rising cases of cancer & high demand for synthetic genes will increase the growth of the transfection technologies market. For instance, according to the data provided by the International Agency for Research on Cancer (IRAC) in 2018, it is estimated that there will be more than 27.5 million new cancer cases by 2040. Also, the two main purposes of transfection are to produce recombinant proteins or to specifically enhance or inhibit gene expression in transfected cells. As such, transfection is a powerful analytical tool for the study of the function and regulation of genes or gene products, for the production of transgenic organisms, and as a method for gene therapy.

Based on product type, the market is segmented into reagents, instruments, and others. Among them, the reagent category is to witness lucrative growth during the forecast period. This growth can be attributed to factors like advancements in transfection technology, global alliances between leading research institutes to spur drug discovery, rising pharmaceutical and biotechnology companies' R&D spending and research activities, an increase in demand for synthetic genes, and a rise in the prevalence of cancer.

On the basis of application, the market is categorized into therapeutic delivery, bio-medical research, protein production, and others. Among these, the therapeutic delivery category is anticipated to register a lucrative CAGR during the forecast period. This is mainly due to the rising demand for precise therapeutic procedures and intensifying research and development activities associated with novel drug and transfection technique discoveries.

Based on technology, the transfection technologies market has been classified into physical transfection, biochemical-based transfection, and viral-vector-based transfection. The viral-vector-based transfection category to hold a significant share in the market during the forecast period. This is mainly due to the growing prominence of gene and cell therapy products and increasing funding activities are the key driving factors fueling the growth of the market.

Based on end-user, the transfection technologies market has been classified into research centers and academic institutes, hospitals and clinics, pharmaceutical and biotechnology companies, and others. The pharmaceutical and biotechnology companies category is to witness higher adoption of transfection technologies during the forecast period. This is mainly due to the growing biopharmaceuticals and technological advancements that will drive the growth of the global transfection technologies market. Besides, the rising government funding to leading research institutes in developed countries for drug development will also drive the transfection technologies market.

For a better understanding of the market adoption of the transfection technologies market, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is anticipated to grow at a substantial CAGR during the forecast period. This is mainly due to the presence of cutting-edge research labs and leading pharmaceutical companies that are continuously contributing to research and development. The full-fledged economies of the states in North America force them to spend an incalculable amount of money on developing modern treatments. Additionally, the rising obesity and breast cancer rates in the US are the major contributor to this sector's dominance in the transfection technologies market. For instance, in 2020, there were 2.3 million women diagnosed with breast cancer and 685 000 deaths globally. As of the end of 2020, there were 7.8 million women who were diagnosed with breast cancer in the past 5 years, making it the world's most prevalent cancer.

Some of the major players operating in the market include: Lonza Group Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories Inc., Roche, QIAGEN, Mirus Bio LLC, SignaGen Laboratories, Genlantis Inc., OZ Biosciences, and Promega Corporation.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Transfection Technologies Market
• 2.2. Research Methodology of the Transfection Technologies Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE TRANSFECTION TECHNOLOGIES MARKET

6 TRANSFECTION TECHNOLOGIES MARKET REVENUE (USD BN), 2020-2028F

7 MARKET INSIGHTS BY PRODUCT TYPE

• 7.1. Reagent
• 7.2. Instrument
• 7.3. Others

8 MARKET INSIGHTS BY APPLICATION

• 8.1. Therapeutic Delivery
• 8.2. Bio-Medical Research
• 8.3. Protein Production
• 8.4. Others

9 MARKET INSIGHTS BY TECHNOLOGY

• 9.1. Physical Transfection
• 9.2. Biochemical-Based Transfection
• 9.3. Viral-Vector-Based Transfection

10 MARKET INSIGHTS BY END-USER

• 10.1. Research Centers and Academic Institutes
• 10.2. Hospitals and Clinics
• 10.3. Pharmaceutical and Biotechnology Companies
• 10.4. Others

11 MARKET INSIGHTS BY REGION

• 11.1. North America
  • 11.1.1. U.S.
  • 11.1.2. Canada
  • 11.1.3. Rest of North America
• 11.2. Europe
  • 11.2.1. Germany
  • 11.2.2. U.K.
  • 11.2.3. France
  • 11.2.4. Italy
  • 11.2.5. Spain
  • 11.2.6. Rest of Europe
• 11.3. Asia-Pacific
  • 11.3.1. China
  • 11.3.2. Japan
  • 11.3.3. India
  • 11.3.4. Rest of Asia-Pacific
• 11.4. Rest of World

12 TRANSFECTION TECHNOLOGIES MARKET DYNAMICS

• 12.1. Market Drivers
• 12.2. Market Challenges
• 12.3. Impact Analysis

13 TRANSFECTION TECHNOLOGIES MARKET OPPORTUNITIES

14 TRANSFECTION TECHNOLOGIES MARKET TRENDS

15 DEMAND AND SUPPLY-SIDE ANALYSIS

• 15.1. Demand Side Analysis
• 15.2. Supply Side Analysis

16 VALUE CHAIN ANALYSIS

17 COMPETITIVE SCENARIO

• 17.1. Competitive Landscape
  • 17.1.1. Porters Five Forces Analysis

18 COMPANY PROFILED

• 18.1. Lonza Group Ltd.
• 18.2. Thermo Fisher Scientific Inc.
• 18.3. Bio-Rad Laboratories Inc.
• 18.4. Roche
• 18.5. QIAGEN
• 18.6. Mirus Bio LLC
• 18.7. SignaGen Laboratories
• 18.8. Genlantis Inc.
• 18.9. OZ Biosciences
• 18.10. Promega Corporation

19 DISCLAIMER